Sickle Cell Disease Market

Table of Content

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions

2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis

2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources

2.4.2. Primary Research
2.4.2.1. Introduction

2.4.2.2. Types
2.4.2.2.1. Qualitative
2.4.2.2.2. Quantitative

2.4.2.3. Advantages

2.4.2.4. Techniques
2.4.2.4.1. Interviews
2.4.2.4.2. Surveys
2.4.2.4.3. Focus Groups
2.4.2.4.4. Observational Research
2.4.2.4.5. Social Media Interactions

2.4.2.5. Stakeholders
2.4.2.5.1. Company Executives (CXOs)
2.4.2.5.2. Board of Directors
2.4.2.5.3. Company Presidents and Vice Presidents
2.4.2.5.4. Key Opinion Leaders
2.4.2.5.5. Research and Development Heads
2.4.2.5.6. Technical Experts
2.4.2.5.7. Subject Matter Experts
2.4.2.5.8. Scientists
2.4.2.5.9. Doctors and Other Hospitals

2.4.2.6. Ethics and Integrity
2.4.2.6.1. Research Ethics
2.4.2.6.2. Data Integrity

2.4.3. Analytical Tools and Databases

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Forecast Methodology
3.1.1. Top-Down Approach
3.1.2. Bottom-Up Approach
3.1.3. Hybrid Approach

3.2. Market Assessment Framework
3.2.1. Total Addressable Market (TAM)
3.2.2. Serviceable Addressable Market (SAM)
3.2.3. Serviceable Obtainable Market (SOM)
3.2.4. Currently Acquired Market (CAM)

3.3. Forecasting Tools and Techniques
3.3.1. Qualitative Forecasting
3.3.2. Correlation
3.3.3. Regression
3.3.4. Time Series Analysis
3.3.5. Extrapolation
3.3.6. Convergence
3.3.7. Forecast Error Analysis
3.3.8. Data Visualization
3.3.9. Scenario Planning
3.3.10. Sensitivity Analysis

3.4. Key Considerations
3.4.1. Demographics
3.4.2. Market Access
3.4.3. Reimbursement Scenarios
3.4.4. Industry Consolidation

3.5. Robust Quality Control
3.6. Key Market Segmentations
3.7. Limitations

4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage
4.2.2.1. Overview of Major Currencies Affecting the Market
4.2.2.2. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Exchange Impact
4.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession
4.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
4.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution

4.2.6. Interest Rates
4.2.6.1. Overview of Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario

4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. R&D Innovation
4.2.11.7. Stock Market Performance
4.2.11.8. Supply Chain
4.2.11.9. Cross-Border Dynamics

5. EXECUTIVE SUMMARY

6. INTRODUCTION
6.1. Chapter Overview
6.2. Overview of Sickle Cell Disease
6.2.1. Key Characteristics of Sickle Cell Disease
6.2.2. Key Applications of the Sickle Cell Disease
6.2.3. Challenges Associated with Sickle Cell Disease

6.3. Future Perspective

7. COMPETITIVE LANDSCAPE
7.1. Chapter Overview
7.2. Sickle Cell Disease Treatment Developers: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters

7.2.4. Sickle Cell Disease Treatment and Drugs: Overall Market Landscape
7.2.4.1. Analysis by Disease Type
7.2.4.2. Analysis by Treatment Type
7.2.4.3. Analysis by Diagnosis Type
7.2.4.4. Analysis by Route of Administration Type
7.2.4.5. Analysis by Drug Class Type
7.2.4.6. Analysis by Complication Type
7.2.4.7. Analysis by Age Group Type
7.2.4.8. Analysis by Distribution Channel Type
7.2.4.9. Analysis by End Users

8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodologies

8.4. Company Competitiveness Analysis: Sickle Cell Disease Treatment Developers
8.4.1. Sickle Cell Disease Treatment Developers Based in North America (Peer Group 1)
8.4.2. Sickle Cell Disease Treatment Developers Based in Europe (Peer Group 2)
8.4.3. Sickle Cell Disease Treatment Developers Based in Asia-Pacific (Peer Group 3)
8.4.4. Sickle Cell Disease Treatment Developers Based in Middle East and North Africa, and Latin America (Peer Group 4)

8.5. Key Findings

9. COMPANY PROFILES
9.1. Chapter Overview
9.2. Allergan
9.2.1. Company Overview
9.2.2. Financial Information
9.2.3. Service / Product Portfolio
9.2.4. Recent Developments and Future Outlook

* Similar details are presented for other below mentioned companies based on information in the public domain

9.3. AstraZeneca
9.4. Amgen
9.5. AbbVie
9.6. Bristol-Myers Squibb Company
9.7. Bayer
9.8. Boehringer Ingelheim International
9.9. Eli Lilly
9.10. Gilead Sciences
9.11. GlaxoSmithKline
9.12. Johnson & Johnson
9.13. Lupin
9.14. Merck
9.15. Novartis
9.16. Pfizer
9.17. Roche
9.18. Sanofi
9.19. Teva Pharmaceutical Industries

10. SWOT ANALYSIS

11. MARKET IMPACT ANALYSIS
11.1. Chapter Overview
11.2. Market Drivers
11.3. Market Restraints
11.4. Market Opportunities
11.5. Market Challenges
11.6. Conclusion

12. GLOBAL SICKLE CELL DISEASE MARKET
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Trends Disruption Impacting Market
12.4. Global Sickle Cell Disease, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

12.5. Multivariate Scenario Analysis
12.5.1. Conservative Scenario
12.5.2. Optimistic Scenario

12.6. Key Market Segmentations

13. MARKET OPPORTUNITIES BASED ON TYPE OF DISEASE
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Revenue Shift Analysis
13.4. Market Movement Analysis
13.5. Penetration-Growth (P-G) Matrix
13.6. Sickle Cell Disease Market for Sickle Cell Anemia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
13.7. Sickle Cell Disease Market for Sickle Hemoglobin-C Disease: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
13.8. Sickle Cell Disease Market for Sickle Beta-Plus Thalassemia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
13.9. Sickle Cell Disease Market for Sickle Hemoglobin-D Disease: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
13.10. Sickle Cell Disease Market for Sickle Hemoglobin-O Disease: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
13.11. Sickle Cell Disease Market for Others: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
13.12. Data Triangulation and Validation

14. MARKET OPPORTUNITIES BASED ON TYPE OF TREATMENT
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Revenue Shift Analysis
14.4. Market Movement Analysis
14.5. Penetration-Growth (P-G) Matrix
14.6. Sickle Cell Disease Market for Blood Transfusion: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

14.7. Sickle Cell Disease Market for Pharmacotherapy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.7.1. Sickle Cell Disease Market for Hydroxyurea: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

14.7.2. Sickle Cell Disease Market for Branded Products: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.7.2.1. Sickle Cell Disease Market for Endari: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.7.2.2. Sickle Cell Disease Market for Adakveo: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.7.2.3. Sickle Cell Disease Market for Oxbryta: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.7.2.4. Sickle Cell Disease Market for Zynteglo: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.7.2.5. Sickle Cell Disease Market for PYRUKYND (Mitapivat): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.7.2.6. Sickle Cell Disease Market for CTX001: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.7.2.7. Sickle Cell Disease Market for Inclacumab: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.7.2.8. Sickle Cell Disease Market for MGTA-145: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.7.2.9. Sickle Cell Disease Market for Vamifeport (VIT-2763): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.7.2.10. Sickle Cell Disease Market for ALXN1820: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.7.2.11. Sickle Cell Disease Market for FT-4202: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.7.2.12. Sickle Cell Disease Market for GBT021601: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

14.8. Sickle Cell Disease Market for Other Treatment: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.9. Data Triangulation and Validation

15. MARKET OPPORTUNITIES BASED ON TYPE OF DIAGNOSIS
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Revenue Shift Analysis
15.4. Market Movement Analysis
15.5. Penetration-Growth (P-G) Matrix
15.6. Sickle Cell Disease Market for Screening Test: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
15.7. Sickle Cell Disease Market for New-Born Screening: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
15.8. Sickle Cell Disease Market for Prenatal Screening: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
15.9. Sickle Cell Disease Market for Other Diagnosis: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
15.10. Data Triangulation and Validation

16. MARKET OPPORTUNITIES BASED ON ROUTE OF ADMINISTRATION
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Revenue Shift Analysis
16.4. Market Movement Analysis
16.5. Penetration-Growth (P-G) Matrix
16.6. Sickle Cell Disease Market for Oral: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.7. Sickle Cell Disease Market for Parenteral: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.8. Data Triangulation and Validation

17. MARKET OPPORTUNITIES BASED ON TYPE OF AGE GROUP
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Revenue Shift Analysis
17.4. Market Movement Analysis
17.5. Penetration-Growth (P-G) Matrix
17.6. Sickle Cell Disease Market for Adults: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.7. Sickle Cell Disease Market for Pediatrics: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.8. Sickle Cell Disease Market for Geriatrics: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.9. Data Triangulation and Validation

18. MARKET OPPORTUNITIES BASED ON TYPE OF DRUG CLASS
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Revenue Shift Analysis
18.4. Market Movement Analysis
18.5. Penetration-Growth (P-G) Matrix
18.6. Sickle Cell Disease Market for Antimetabolites: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.7. Sickle Cell Disease Market for Amino Acids: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.8. Sickle Cell Disease Market for NSAIDs: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.9. Sickle Cell Disease Market for Monoclonal Antibodies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.10. Sickle Cell Disease Market for Others: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.11. Data Triangulation and Validation

19. MARKET OPPORTUNITIES BASED ON TYPE OF COMPLICATION
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Revenue Shift Analysis
19.4. Market Movement Analysis
19.5. Penetration-Growth (P-G) Matrix
19.6. Sickle Cell Disease Market for Stroke: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.7. Sickle Cell Disease Market for Acute Chest Syndrome: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.8. Sickle Cell Disease Market for Pulmonary Hypertension: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.9. Sickle Cell Disease Market for Organ Damage: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.10. Sickle Cell Disease Market for Others: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.11. Data Triangulation and Validation

20. MARKET OPPORTUNITIES BASED ON TYPE OF DISTRIBUTION CHANNEL
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Revenue Shift Analysis
20.4. Market Movement Analysis
20.5. Penetration-Growth (P-G) Matrix
20.6. Sickle Cell Disease Market for Hospital Pharmacies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.7. Sickle Cell Disease Market for Retail Pharmacies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.8. Sickle Cell Disease Market for Online Pharmacies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.9. Data Triangulation and Validation

21. MARKET OPPORTUNITIES BASED ON TYPE OF END USER
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Revenue Shift Analysis
21.4. Market Movement Analysis
21.5. Penetration-Growth (P-G) Matrix
21.6. Sickle Cell Disease Market for Hospitals: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.7. Sickle Cell Disease Market for Specialty Clinics: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.8. Sickle Cell Disease Market for Other End Users: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.9. Data Triangulation and Validation

22. MARKET OPPORTUNITIES FOR SICKLE CELL DISEASE IN NORTH AMERICA
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Revenue Shift Analysis
22.4. Market Movement Analysis
22.5. Penetration-Growth (P-G) Matrix

22.6. Sickle Cell Disease Market in North America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.6.1. Sickle Cell Disease Market in the US: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.6.2. Sickle Cell Disease Market in Canada: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.6.3. Sickle Cell Disease Market in Mexico: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

22.7. Data Triangulation and Validation

23. MARKET OPPORTUNITIES FOR SICKLE CELL DISEASE IN EUROPE
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Revenue Shift Analysis
23.4. Market Movement Analysis
23.5. Penetration-Growth (P-G) Matrix

23.6. Sickle Cell Disease Market in Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.1. Sickle Cell Disease Market in Germany: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.2. Sickle Cell Disease Market in France: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.3. Sickle Cell Disease Market in Italy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.4. Sickle Cell Disease Market in Spain: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.5. Sickle Cell Disease Market in the UK: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.6. Sickle Cell Disease Market in Rest of Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

23.7. Data Triangulation and Validation

24. MARKET OPPORTUNITIES FOR SICKLE CELL DISEASE IN ASIA-PACIFIC
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Revenue Shift Analysis
24.4. Market Movement Analysis
24.5. Penetration-Growth (P-G) Matrix

24.6. Sickle Cell Disease Market in Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.1. Sickle Cell Disease Market in China: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.2. Sickle Cell Disease Market in India: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.3. Sickle Cell Disease Market in Japan: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.4. Sickle Cell Disease Market in South Korea: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.5. Sickle Cell Disease Market in Rest of the Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

24.7. Data Triangulation and Validation

25. MARKET OPPORTUNITIES FOR SICKLE CELL DISEASE IN MIDDLE EAST AND NORTH AFRICA (MENA)
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Revenue Shift Analysis
25.4. Market Movement Analysis
25.5. Penetration-Growth (P-G) Matrix

25.6. Sickle Cell Disease Market in Middle East and North Africa (MENA): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.6.1. Sickle Cell Disease Market in Egypt: Historical Trends (Since 2020) and Forecasted Estimates (Till 205)
25.6.2. Sickle Cell Disease Market in Saudi Arabia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.6.3. Sickle Cell Disease Market in United Arab Emirates (UAE): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.7. Data Triangulation and Validation

26. MARKET OPPORTUNITIES FOR SICKLE CELL DISEASE IN LATIN AMERICA
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Revenue Shift Analysis
26.4. Market Movement Analysis
26.5. Penetration-Growth (P-G) Matrix

26.6. Sickle Cell Disease Market in Latin America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.1. Sickle Cell Disease Market in Argentina: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.2. Sickle Cell Disease Market in Brazil: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

26.7. Data Triangulation and Validation

27. APPENDIX 1: TABULATED DATA

28. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

29. CUSTOMIZATION OPPORTUNITIES

30. ROOTS SUBSCRIPTION SERVICES

31. AUTHOR DETAIL